Dashboard
Manage Tickers

INTTINTEST CORP

NYSE intest.com


$ 10.14 $ 0.11 (1.05 %)    

Tuesday, 14-May-2024 11:44:07 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 443.94 $ -0.85 (-0.19 %)
DIA $ 394.42 $ -0.67 (-0.17 %)
SPY $ 521.23 $ -0.95 (-0.18 %)
TLT $ 90.48 $ -0.13 (-0.14 %)
GLD $ 217.54 $ -0.30 (-0.14 %)
$ 9.85
$ 10.03
$ 10.03 x 103
$ 10.16 x 200
$ 9.95 - $ 10.20
$ 9.71 - $ 27.17
138,473
na
119.76M
$ 1.29
$ 16.66
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-23-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-26-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-28-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-27-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-29-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-26-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-13-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lake-street-maintains-buy-on-intest-lowers-price-target-to-16
Lake Street Maintains Buy on inTest, Lower...
05/07/2024 15:33:58

Lake Street analyst Jaeson Schmidt maintains inTest (AMEX:INTT) with a Buy and lowers the price target from $19 to $16.

intest-cuts-fy24-revenue-from-145m-155m-to-140m-150m-vs-149797m-est
InTest Cuts FY24 Revenue From $145M-$155M ...
05/06/2024 20:53:31

intest-sees-q2-2024-adj-eps-010-016-vs-020-est-revenue-34m-36m-vs-33750m-est
InTest Sees Q2 2024 Adj. EPS $0.10-$0.16 V...
05/06/2024 20:53:22

intest-q1-2024-adj-eps-010-beats-009-estimate-sales-29824m-beat-29050m-estimate
inTest Q1 2024 Adj EPS $0.10 Beats $0.09 E...
05/06/2024 20:22:47

inTest (AMEX:INTT) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.09 by 11.11 p...

recap-intest-q4-earnings
Recap: inTest Q4 Earnings
03/27/2024 21:50:07

intest-q4-2023-adj-eps-016-beats-014-estimate-sales-27884m-miss-29152m-estimate
inTest Q4 2023 Adj EPS $0.16 Beats $0.14 E...
03/27/2024 21:46:57

inTest (AMEX:INTT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.14 by 14.29 p...

intest-to-restate-q3-and-first-nine-months-2023-financial-statements-expects-to-report-material-weakness-in-its-internal-control-over-financial-reporting
inTEST To Restate Q3 And First Nine Months...
03/12/2024 20:26:40

The restatement pertains to deferral of revenue related to purchases on behalf of certain customers associated with "last t...

intest-updates-full-year-2024-guidance-due-to-alfamation-acquisition-boosts-2024-revenue-outlook-from-125m-130m-to-145m-155m-est-125795m
inTEST Updates Full Year 2024 Guidance Due...
03/12/2024 20:23:52

The acquisition is expected to be dilutive to earnings per diluted share in 2024, but accretive to non-GAAP adjusted EPS due to...

intest-acquires-alfamation-spa-no-terms-disclosed
inTEST Acquires Alfamation S.p.A.; No Term...
03/12/2024 20:19:59

Alfamation will become a part of the Electronic Test division within inTEST. At current exchange rates, Alfamation's annual...

12-information-technology-stocks-moving-in-mondays-after-market-session
12 Information Technology Stocks Moving In...
03/04/2024 21:32:13

intest-prelim-q4-revenue-284m-eps-014-sees-q1-revenue-28m-30m-eps-008-013-co-to-reschedule-q4-earnings-release
inTEST Prelim. Q4 Revenue ~$28.4M, EPS $0....
02/29/2024 22:17:29

intest-delays-q4-2023-earnings-release-says-it-requires-additional-time-to-complete-year-end-audit-and-review-process-preliminary-q4-revenue-284m-est-29152m
inTEST Delays Q4 2023 Earnings Release, Sa...
02/29/2024 22:17:19

earnings-outlook-for-intest
Earnings Outlook For inTest
02/29/2024 14:01:36

12-information-technology-stocks-moving-in-tuesdays-after-market-session
12 Information Technology Stocks Moving In...
12/12/2023 21:30:59

intest-board-approves-stock-repurchase-plan-for-up-to-10m-of-common-stock-through-november-17-2024
inTEST Board Approves Stock Repurchase Pla...
11/27/2023 21:16:24

intest-corp-files-prospectus-for-up-to-100m-offering
inTEST Corp Files Prospectus For Up To $10...
11/09/2023 22:00:22

$100,000,000inTEST CorporationCommon StockPreferred StockWarrantsPurchase ContractsRightsUnitsWe may offer to the public from t...

earnings-scheduled-for-november-3-2023
Earnings Scheduled For November 3, 2023
11/03/2023 11:12:01

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per ...

intest-sees-q4-revenue-of-28m---30m-vs-324m-est-adj-eps-of-012---017-vs-02-est
inTEST Sees Q4 Revenue Of $28M - $30M Vs. ...
11/03/2023 10:39:46

intest-cuts-fy23-revenue-guidance-from-127m---131m-to-125m---127m-vs-1295m-est
inTEST Cuts FY23 Revenue Guidance From $12...
11/03/2023 10:37:55

intest-q3-adj-eps-028-beats-025-estimate-sales-3266m-beat-3265m-estimate
inTest Q3 Adj EPS $0.28 Beats $0.25 Estima...
11/03/2023 10:35:33

inTest (AMEX:INTT) reported quarterly adjusted earnings of $0.28 per share which beat the analyst consensus estimate of $0.25 b...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION